编号：2021-001 证券代码：002144 证券简称：宏达高科 宏达高科控股股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|------------------------------|--------------------------------------------------------------| | | | | | 投资者关系活 | □ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 □ | 业绩说明会 | | | □ 新闻发布会 □ | 路演活动 | | | □ 现场参观 □ | 现场调研 | | | ■ 其他 : | 投资者接待日（请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | | 沈亿万、王伟丽、王慧、凌良、陈洪、周华健、胡佳宇 | | 时间 | 2021 年 5 月 18 日 | 15:30-17:00 | | 地点 | 浙江省海宁市许村镇建设路 | 118 号公司会议室 | | 上市公司接待 | | 董事长沈国甫、董事兼总经理许建舟、董事兼副总经理顾伟锋、董 | ...

宏达高科控股股份有限公司 2022 年第三季度报告 证券代码：002144 证券简称：宏达高科 公告编号：2022-020 3.第三季度报告是否经过审计 重要内容提示： □是否 一、主要财务数据 （一）主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大 遗漏，并承担个别和连带的法律责任。 宏达高科控股股份有限公司 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 | 项目 | 本报告期金额 | 年初至报告期期末金额 | 说明 | | --- | --- | --- | --- | | 非流动资产处置损益（包括已计提 | 0.00 | -9,226.75 | | | 资产减值准备的冲销部分） | | | | | 计入当期损益的政府补助（与公司 正常经营业务密切相关，符合国家 | 894,285.10 | ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥273,423,542.60, a decrease of 3.94% compared to ¥284,650,140.98 in the same period last year[23]. - The net profit attributable to shareholders was ¥43,152,169.43, down 44.17% from ¥77,289,557.29 year-on-year[23]. - The net cash flow from operating activities was ¥11,138,081.95, reflecting a significant decline of 74.95% compared to ¥44,456,651.08 in the previous year[23]. - The basic earnings per share decreased by 45.45% to ¥0.24 from ¥0.44 in the same period last year[23]. - The total comprehensive income for the first half of 2022 was CNY 37,295,210.86, significantly lower than CNY 76,868,278.27 in the first half of 2021, representing a decrease of about 51.5%[132]. - The total profit for the first half of 2022 was CNY 46,920,717.12, compared to CNY 86,304,827.65 in the first half of 2021, reflecting a decrease of about 45.0%[130]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,100,710,771.02, representing a slight increase of 0.69% from ¥2,086,217,456.64 at the end of the previous year[23]. - The company's total liabilities decreased to CNY 756,843,255.90 from CNY 733,315,634.29, indicating a reduction of approximately 3.1%[123]. - The total liabilities at the end of the reporting period were 1,000,000,000.00, which is a significant increase compared to the previous year[145]. Revenue Segmentation - The fabric weaving segment generated revenue of CNY 147.36 million, accounting for 53.90% of total revenue, with a year-on-year increase of 8.15%[40]. - The medical device segment reported revenue of CNY 29.92 million, representing a decline of 13.12% year-on-year[41]. - The company's total sales revenue from direct sales was approximately CNY 158.33 million, with a gross margin of 27.03%[44]. Research and Development - The company’s R&D investment was CNY 10.09 million, a decrease of 28.83% compared to the previous year[37]. - The subsidiary, Weirder, has over 120 patents related to ultrasound diagnosis and treatment, emphasizing its strong R&D capabilities[33]. Market and Competition - The company is exposed to risks related to macroeconomic conditions, downstream market conditions, and raw material prices in the textile industry[5]. - The company faces market competition risks in its textile and medical device sectors, influenced by global economic fluctuations and increasing competition from both domestic and international players[62]. - The company is exposed to raw material price volatility risks, particularly for nylon and polyester yarns, which could impact production costs[63]. Environmental Compliance - The total greenhouse gas emissions for the first half of 2022 amounted to 19,622.669 tons of CO2, with a 10% reduction in steam consumption per ton of fabric achieved through insulation measures[77]. - The company has maintained compliance with environmental regulations, with all monitored data meeting standards during the reporting period[76]. - The company has implemented effective pollution control measures, with stable operation of pollution prevention facilities and a low failure rate[73]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,266[108]. - The largest shareholder, Shen Guofu, holds 23.36% of the shares, totaling 41,294,390 shares[108]. - The total number of unrestricted shares at the end of the reporting period was 137,899,605, accounting for 78.01% of total shares[105]. Financial Management - The company has entrusted financial management with a total of 61.5 million yuan, with an occurrence amount of 5 million yuan and no overdue amounts[99]. - There are no overdue receivables from entrusted financial management[99]. - The company has not reported any derivative investments during the reporting period[57]. Future Plans and Strategies - The company plans to expand into high-end passenger vehicle markets and enhance the development of functional apparel fabrics[36]. - The company plans to enhance its market expansion strategies in the upcoming quarters, focusing on new product development and technological advancements[144]. - The company is focusing on strategic acquisitions to enhance its competitive position in the market[148]. Corporate Governance - The company has not made any changes to its board of directors or senior management during the reporting period[68]. - The company did not experience any major litigation or arbitration matters during the reporting period[85]. - There were no significant related party transactions during the reporting period[87].

宏达高科控股股份有限公司 2022 年第一季度报告全文 证券代码：002144 证券简称：宏达高科 公告编号：2022-011 宏达高科控股股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或 重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | 项目 | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 116,414,221.46 | 128,542,967.33 | -9.44% | | 归属于上市公司股东的净利润（元） | 15,555,857.99 | 23,9 ...

Financial Performance - The company's operating revenue for 2021 was CNY 601,036,760.90, representing a 30.19% increase compared to CNY 461,677,366.93 in 2020[20]. - The net profit attributable to shareholders for 2021 was CNY 64,866,464.75, a slight increase of 1.43% from CNY 63,951,711.86 in 2020[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses surged by 423.44% to CNY 12,505,567.43 from CNY 2,389,119.82 in 2020[20]. - The net cash flow from operating activities increased by 22.34% to CNY 108,013,105.44 compared to CNY 88,291,794.36 in 2020[20]. - The total assets at the end of 2021 were CNY 2,086,217,456.64, reflecting a 7.11% increase from CNY 1,947,784,415.31 at the end of 2020[20]. - The net assets attributable to shareholders at the end of 2021 were CNY 1,859,360,967.15, up 5.39% from CNY 1,764,321,090.21 at the end of 2020[20]. - The basic earnings per share for 2021 were CNY 0.37, a 2.78% increase from CNY 0.36 in 2020[20]. - The weighted average return on net assets for 2021 was 3.58%, slightly down from 3.67% in 2020[20]. Revenue Breakdown - In 2021, the company's total revenue for the four quarters was approximately ¥601 million, with the highest revenue in Q4 at ¥164.9 million[25]. - The net profit attributable to shareholders for the year was approximately ¥64 million, with a significant loss of ¥33.2 million in Q4[25]. - The net cash flow from operating activities for the year totaled approximately ¥108 million, with Q2 showing the highest cash flow of ¥36.98 million[25]. - The textile weaving segment saw a significant revenue increase of 45.54%, reaching CNY 319.03 million, contributing 53.08% to total operating revenue[42]. - The medical device segment, specifically the subsidiary Weirder, generated operating revenue of CNY 59.27 million, a decrease of 3.18% year-on-year[42]. Market Conditions - The company operates in the textile industry, particularly in automotive interior fabrics, which is closely linked to the automotive sector's market conditions[6]. - The automotive market in China experienced a production and sales increase of 3.4% and 3.8% respectively, marking a recovery after three years of decline[31]. - The textile industry saw a revenue increase of 12.3% year-on-year, with total revenue reaching ¥51,749 billion in 2021[32]. - The medical device market in China continues to grow, driven by factors such as GDP growth and an aging population, indicating significant future potential[33]. Strategic Initiatives - The company plans to distribute a cash dividend of CNY 1.00 per 10 shares to all shareholders, based on a total of 176,762,528 shares[6]. - The company plans to expand its product line in the ultrasound diagnostic equipment sector and enhance its market presence in veterinary ultrasound[38]. - The company aims to develop high-value customer relationships in the new energy vehicle sector, ensuring sustained growth and improved service levels[86]. - The company plans to enhance its fabric weaving and medical device sectors, focusing on R&D and production capabilities to maintain its industry position and explore new markets[86]. Governance and Management - The company has established a governance structure that complies with the requirements of the China Securities Regulatory Commission and the Shenzhen Stock Exchange, ensuring effective decision-making and operational coordination[94]. - The board of directors consists of nine members, including three independent directors, and operates independently according to established rules[97]. - The company maintains complete independence from its controlling shareholder in terms of business, personnel, assets, and finances, ensuring autonomous operational capabilities[103]. - The company has not experienced any changes in the tenure of directors, supervisors, or senior management during the reporting period[108]. Environmental Compliance - The company is classified as a key pollutant discharge unit by the environmental protection department, with total emissions of 38.31 tons of CODcr and 3.831 tons of ammonia nitrogen, both within the permitted limits[146]. - The wastewater treatment facility was upgraded in 2015, achieving a daily processing capacity of 8,000 tons, and has consistently met the discharge standards without any violations reported in 2021[151]. - The company has maintained a 100% compliance rate for environmental self-monitoring data transmission and public disclosure in 2021[149]. - There were no non-compliance issues reported regarding the company's environmental practices during routine inspections by environmental authorities in 2021[151]. Employee and Compensation Policies - The total number of employees at the end of the reporting period was 538, including 379 at the parent company and 150 at major subsidiaries[129]. - The company has established a competitive and fair salary policy, ensuring that employee compensation is based on performance, skills, and market levels[130]. - The company emphasizes talent development through a multi-level training program, including various training types such as safety production and professional skills enhancement[131]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 4.4414 million[120]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 1.32 billion yuan[116]. - New product development is underway, with two innovative products expected to launch in Q3 2023, aiming to capture a larger market share[116]. - A strategic acquisition is in progress, with negotiations to acquire a competitor valued at approximately 300 million yuan, expected to enhance market capabilities[116]. - The management team emphasized the importance of sustainability, aiming to reduce carbon emissions by 25% over the next five years[116].

宏达高科控股股份有限公司 2021 年第三季度报告 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 宏达高科控股股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或 重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 证券代码：002144 证券简称：宏达高科 公告编号：2021-031 3.第三季度报告是否经过审计 □ 是 √ 否 □ 是 √ 否 | 项目 | 本报告期 | 本报告期比上年同期增 | 年初至报告期末 | 年初至报告期末比上年 | | --- | --- | --- | --- | --- | | | | 减 | | 同期增减 | | 营业收入（元） | 151,482,400.07 | 15.13% | 436,132,541.05 | 35. ...

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 284,650,140.98, representing a 50.04% increase compared to CNY 189,721,295.42 in the same period last year[21]. - The net profit attributable to shareholders of the listed company reached CNY 77,289,557.29, a significant increase of 125.77% from CNY 34,233,305.81 year-on-year[21]. - The net cash flow from operating activities was CNY 44,456,651.08, up 166.76% from CNY 16,665,279.25 in the previous year[21]. - Basic earnings per share increased to CNY 0.44, reflecting a growth of 131.58% compared to CNY 0.19 in the same period last year[21]. - The company reported a significant increase in the net profit after deducting non-recurring gains and losses, which was CNY 34,921,478.47, up 38.25% from CNY 25,260,535.28 year-on-year[21]. - The company achieved a revenue of CNY 284.65 million in the first half of 2021, representing a year-on-year increase of 50.04%[33]. - The net profit attributable to shareholders reached CNY 77.29 million, a significant increase of 125.77% compared to the previous year[33]. - The company reported a net cash flow from operating activities of CNY 444.57 million, a substantial increase of 166.76% year-on-year[35]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,016,517,570.12, a 3.53% increase from CNY 1,947,784,415.31 at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company were CNY 1,823,419,294.70, up 3.35% from CNY 1,764,321,090.21 at the end of the previous year[21]. - The company's total equity reached CNY 1,826,670,266.78, up from CNY 1,767,478,241.31, which is an increase of approximately 3.4%[126]. - Total current liabilities increased to CNY 157,566,694.83 from CNY 145,293,745.69, marking an increase of about 8.5%[125]. - The company's total liabilities increased to CNY 125,563,025.95, up from CNY 120,242,270.47, indicating a rise of 2.7%[130]. Revenue Segmentation - The company's main business in fabric weaving generated a revenue of CNY 155.71 million, up 72.07% year-on-year[34]. - The fabric weaving segment generated CNY 136,255,236.41, accounting for 47.87% of total revenue, with a year-on-year growth of 59.06%[37]. - The medical device segment reported revenue of CNY 34,437,536.07, reflecting a 42.21% increase from CNY 24,216,568.57 in the previous year[37]. - The subsidiary, Weirder, reported a net profit of CNY 15.38 million, an increase of 19.16% year-on-year, driven by advancements in ultrasound diagnostic and treatment equipment[34]. Research and Development - R&D investment increased by 61.75% to CNY 141.76 million, reflecting the company's commitment to innovation and product development[35]. - Research and development expenses increased to CNY 14,176,115.55 in the first half of 2021, up 61.8% from CNY 8,764,399.79 in the first half of 2020[131]. - The company holds 117 patents related to ultrasound diagnosis and treatment, showcasing its strong R&D capabilities[32]. Market and Competition - The automotive market showed resilience with domestic passenger car production and sales reaching 9.84 million and 10.01 million units respectively, up 26.8% and 27.0% year-on-year[29]. - The company plans to enhance the development of automotive interior fabrics for new energy vehicles, responding to the growing market demand[29]. - The company faces market competition risks in its fabric weaving and medical device businesses, influenced by macroeconomic conditions and increasing competition from both domestic and international players[58]. - The company is exposed to international market risks due to rising trade protectionism and currency fluctuations, which may impact its export growth[59]. Cash Flow and Investments - The cash and cash equivalents increased by 233.93% to CNY 896.14 million, attributed to improved operating cash flow and investment activities[35]. - The company achieved a net investment income of CNY 20,673,544.24, primarily from equity method investments and idle fund management[47]. - The company received CNY 251,831,450.73 in cash from sales of goods and services during the first half of 2021, compared to CNY 178,891,573.48 in the same period of 2020, indicating an increase of approximately 41%[140]. - Investment activities generated a net cash flow of CNY 63,385,735.30 in the first half of 2021, compared to CNY 12,762,070.25 in the previous year, reflecting a growth of about 397%[142]. Shareholder Information - The total number of shares increased from 176,762,528 to 176,762,528, with no change in the overall number of shares[104]. - The largest shareholder, Shen Guofu, holds 22.71% of the shares, totaling 40,150,081 shares, with an increase of 1,261,245 shares during the reporting period[109]. - The total number of ordinary shareholders at the end of the reporting period was 17,255[109]. - The company reported no changes in the approval status of share changes, transfer situations, or repurchase implementation progress[105][106]. Compliance and Governance - The company has not faced any administrative penalties related to environmental issues during the reporting period, indicating compliance with environmental regulations[72]. - The company has not experienced any changes in its board of directors or senior management during the reporting period, ensuring stability in leadership[64]. - The company did not engage in any asset or equity acquisitions or sales during the reporting period[85]. - The financial report for the first half of 2021 has not been audited[121]. Risk Management - The company is exposed to raw material price fluctuation risks, particularly in its fabric weaving business, which relies on nylon, polyester, and other raw materials[58]. - The company has a significant portion of inventory within current assets, which poses a risk of inventory devaluation if market prices decline during turnover periods[59]. - The company has established strict protocols to protect its core technologies, which are critical to its competitive advantage in the medical device industry[59]. - The company has a risk of bad debts due to increasing accounts receivable as sales scale expands, particularly if macroeconomic conditions worsen[59].

证券代码：002144 股票简称：宏达高科 公告编号：2021-017 宏达高科控股股份有限公司 关于举办投资者接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 宏达高科控股股份有限公司（以下简称"公司"）已于 2021 年 4 月 20 日披露《2020 年度报告及其摘要》，为便于广大投资者深入全面地了解公司情况，公司将举办投资者 接待日活动，现将有关事项公告如下： 1、接待时间 2021 年 5 月 18 日 15:30-16:30 2、接待方式 采用现场接待方式 3、接待地点 浙江省海宁市许村镇建设路 118 号宏达高科控股股份有限公司三楼会议室。 4、登记预约方式 请来访投资者于 2021 年 5 月 13 日至 14 日工作时间与公司证券部联系，并同时提 供调研提纲，以便接待登记和安排。 联系人：马强强； 电话：0573-87550882；传真：0573-87552681。 5、公司出席人员 公司董事长沈国甫先生、独立董事平衡先生、总经理许建舟先生、财务总监王凤 娟女士、董事会秘书马强强先生（如有特殊情况，参与人员会有调整）。 6、注 ...

宏达高科控股股份有限公司 Hongda High-Tech Holding Co.,Ltd. （002144） 2021 年第一季度报告全文 2021 年 4 月 宏达高科控股股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 | 项目 | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 128,542,967.33 | 107,664,130.42 | 19.39% | | 归属于上市公司股东的净利润（元） | 23,957,264.79 | 16,353,569.18 | 46.50% | | 归属于上市公司股东的扣除非经常性损 益的净利润（元） | 16,238,135.04 | 14,254,669.78 | 13.91% | | 经营活动产生的现金流量净额（元） | 7,474,078.48 | 2,919,683.37 | 155.99% | | 基本每 ...

Financial Performance - The company's operating revenue for 2020 was approximately ¥461.68 million, a decrease of 15.03% compared to ¥543.32 million in 2019[18]. - The net profit attributable to shareholders for 2020 was approximately ¥63.95 million, down 22.51% from ¥82.53 million in 2019[18]. - The net cash flow from operating activities was approximately ¥88.29 million, representing a decline of 29.24% compared to ¥124.78 million in 2019[18]. - The basic earnings per share for 2020 was ¥0.36, a decrease of 23.40% from ¥0.47 in 2019[18]. - Total assets at the end of 2020 were approximately ¥1.95 billion, a slight increase of 0.24% from ¥1.94 billion at the end of 2019[18]. - The net assets attributable to shareholders at the end of 2020 were approximately ¥1.76 billion, an increase of 2.28% from ¥1.72 billion at the end of 2019[18]. - The company reported a significant drop of 96.44% in net profit after deducting non-recurring gains and losses, amounting to approximately ¥2.39 million in 2020[18]. - The weighted average return on net assets for 2020 was 3.67%, down from 4.87% in 2019[18]. - Total revenue for the year was 440,677,366.93 CNY, with a quarterly breakdown of 107,664,130.42 CNY in Q1, 82,057,165.00 CNY in Q2, 131,572,197.83 CNY in Q3, and 140,383,873.68 CNY in Q4[22]. - Net profit attributable to shareholders for the year was 64,951,711.86 CNY, with quarterly figures of 16,353,569.18 CNY in Q1, 17,879,736.63 CNY in Q2, 23,192,011.81 CNY in Q3, and 6,526,394.24 CNY in Q4[22]. Revenue and Segments - The fabric weaving segment generated 219.20 million yuan in revenue, a decline of 30.35% from the previous year[39]. - The medical device segment saw a revenue increase of 31.66%, reaching 12.51 million yuan, with a net profit growth of 126.15% to 1.84 million yuan[35]. - Domestic revenue accounted for 71.53% of total revenue, while international revenue decreased by 30.34% to 131.45 million yuan[39]. - The company’s revenue from government subsidies increased to 14,965,649.42 CNY in 2020, up from 10,965,516.84 CNY in 2019[23]. Investments and Acquisitions - The company invested 40 million CNY to acquire a 4% stake in Hangzhou Fute Technology Co., Ltd. in October 2020[29]. - The company signed a significant sales contract in July 2020, acquiring a 70% stake in Zhejiang Jiaxing Xinhang Medical Equipment Co., Ltd. for CNY 7,000,000[49]. - The company reported a net profit of 19,316,725.69 yuan from its subsidiary, Shenzhen Weierde Medical Electronics Co., which has a registered capital of 150,000,000.00 yuan[79]. - The company’s subsidiary, Haining Hongda Microfinance Co., reported a net profit of 96,500,944.61 yuan, with total assets of 1,167,262,524.82 yuan[79]. Research and Development - The subsidiary, Weierde, has developed over 110 patents related to ultrasound diagnosis and treatment, indicating a strong focus on R&D[31]. - Research and development expenses increased by 18.82% to CNY 34,245,482.93 in 2020 from CNY 28,820,803.62 in 2019[53]. - The company is actively developing new products, including high-performance automotive interior fabrics and new medical devices, to drive growth[58]. - The company will increase R&D investment in the fabric weaving sector to maintain its technological leadership in automotive interior fabrics and expand into new areas such as rail transportation and civil aviation[84]. Market Conditions and Risks - The company faced significant impacts from the COVID-19 pandemic, particularly in the domestic passenger vehicle market, affecting its main business revenue[6]. - The company anticipates stable growth in the automotive market driven by urbanization and increasing disposable income[81]. - The medical device industry is expected to benefit significantly from the "Healthy China 2030" initiative, promoting rapid development opportunities[82]. - The company faces market competition risks, particularly in the automotive interior fabric business, which is heavily influenced by macroeconomic conditions[85]. - The company is exposed to raw material price fluctuation risks, as its fabric weaving business relies on materials like nylon and polyester[86]. Corporate Governance - The company has a diverse board with members holding various professional backgrounds, enhancing governance and strategic oversight[149][150][151][152]. - The company’s independent directors include professionals with expertise in finance, engineering, and law, contributing to a well-rounded decision-making process[153][154]. - The company has maintained a stable management team, with several members having long tenures, which supports continuity in operations and strategy[155]. - The governance structure complies with regulatory requirements, with a clear division of responsibilities among the board, supervisory board, and management[168]. Environmental Compliance - The company has implemented effective pollution control measures, with all monitored pollutants meeting regulatory standards in 2020[125]. - The company completed the second revision of its emergency response plan for environmental incidents in October 2020, ensuring compliance with local regulations[126]. - The wastewater treatment facility has a daily processing capacity of 8,000 tons, designed to meet the GB 4287-2012 discharge standards, with a lifespan of 20 years[127]. - The company strictly complied with environmental regulations during the reporting period, with no violations or illegal records reported[127]. Shareholder Information - The total number of shares is 176,762,528, with 20.97% being limited shares and 79.03% being unrestricted shares[132]. - The largest shareholder, Shen Guofu, holds 22.00% of the shares, totaling 38,888,836 shares[134]. - The cash dividend payout ratio for 2020 was 27.64% of the net profit attributable to the parent company, which was RMB 63,951,711.86[94]. - The company has maintained a consistent cash dividend of RMB 17,676,252.80 over the past three years[94]. Financial Management - The company has not engaged in any major mergers or acquisitions during the reporting period[97]. - The company has not engaged in any high-risk wealth management or loan activities during the reporting period, reflecting a cautious approach to financial management[120]. - The company reported zero significant defects in financial and non-financial reporting, indicating strong internal controls[188]. - The audit opinion was a standard unqualified opinion, affirming that the financial statements fairly present the company's financial position[193].